Amino acid conjugates of quetiapine, process for making and using the same

Patent metadata

Field	Value
Publication number	US-10010615-B2
Application number	US-201715595374-A
Country	US
Kind code	B2
Filing date	May 15, 2017
Priority date	Dec 31, 2009
Publication date	Jul 3, 2018
Grant date	Jul 3, 2018

Abstract

The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating amino acids. The present technology also provides methods of treating patients, pharmaceutical compositions and methods of synthesizing conjugates of the present technology.

First claim

What is claimed is:

1. A composition comprising 2-(2-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)ethoxy)ethanol (quetiapine) conjugated to phenylalanine via an ester bond, a salt of the conjugate, or their combination.

2. The composition of claim 1 , wherein the salt is a pharmaceutically acceptable salt.

3. The composition of claim 1 , wherein the composition has a higher relative bioavailability than non-conjugated quetiapine when administered orally to a mammalian or human subject.

4. The composition of claim 1 , wherein the composition is formulated for oral, suppository, or parenteral administration.

5. The composition of claim 4 , wherein the composition formulated for oral administration is selected from the group consisting of a tablet, capsule, caplet, pill, troche, lozenge, liquid solution, suspension, elixir, powder, syrup, dragée, gel, slurry, granule, wafer, and oral thin film.

6. The composition of claim 1 , wherein the conjugate is present in an amount of between about 1 mg and about 2000 mg per unit dose.

7. The composition of claim 6 , wherein the conjugate is present in an amount of between about 150 and about 800 mg per unit dose.

8. The composition of claim 6 , wherein the presence of quetiapine is based on molar equivalent of unconjugated quetiapine.

9. The composition of claim 7 , wherein the presence of quetiapine is based on molar equivalent of unconjugated quetiapine.

10. The composition of claim 1 , further comprising one or more of: lithium, divalproex, adjuvants, antiadherents, binders, coatings, disintegrants, fillers, flavors and colors, glidants, lubricants, preservatives, sorbents, sweeteners, or a combination thereof.

11. The composition of claim 1 , wherein the salt is selected from the group consisting of a hydrochloride salt, a hydrobromide salt, a hydroiodide salt, a sulfate, a phosphate, an organic acid salt, a nitrate, a benzoate, and mixtures thereof.

12. The composition of claim 11 , wherein the salt is the organic acid salt selected from the group consisting of a mesylate salt, a besylate salt, a tosylate salt, an oxalate salt, a fumarate salt, a triflate salt, a citrate salt, a malate salt, a tartrate salt, and mixtures thereof.

13. The composition of claim 1 , wherein the conjugate is a prodrug.

14. The composition of claim 13 , wherein the composition comprises a pharmaceutically acceptable salt of the prodrug.

15. A composition comprising a pharmaceutically acceptable excipient and quetiapine, conjugated to phenylalanine via an ester bond wherein the conjugate is represented by any one of the following structures:

16. The composition of claim 15 , wherein the salt is a pharmaceutically acceptable salt.

17. The composition of claim 16 , wherein the salt is selected from the group consisting of a hydrochloride salt, a hydrobromide salt, a hydroiodide salt, a sulfate, a phosphate, an organic acid salt, a nitrate, a benzoate, and mixtures thereof.

18. The composition of claim 17 , wherein the salt is the organic acid salt selected from the group consisting of a mesylate salt, a besylate salt, a tosylate salt, an oxalate salt, a fumarate salt, a triflate salt, a citrate salt, a malate salt, a tartrate salt, and mixtures thereof.

19. The composition of claim 15 , wherein the conjugate is a prodrug.

20. The composition of claim 19 , wherein the composition comprises a pharmaceutically acceptable salt of the prodrug.

21. A compound represented by one of the following structures:

Assignees

• Kempharm Inc

Inventors

• Mickle Travis
• Guenther Sven
• Bera Sanjib

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/20

  Hypnotics; Sedatives · CPC title

• C07D267/18

  [b, e]-condensed · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C07D281/16

  [b, f]-condensed · CPC title